Hausen A, Fuchs D, Reibnegger G, Wachter H
Cancer. 1984 Apr 1;53(7):1634-6. doi: 10.1002/1097-0142(19840401)53:7<1634::aid-cncr2820530736>3.0.co;2-8.
A diagnostic test for detecting malignancies has been reported by Rao and associates. This test has been extended by Trehan and associates as an index of disease status in acute myeloblastic leukemic patients on antileukemic drugs. The authors were able to demonstrate that by using the described assay various pteridines are measured and not exclusively 6-hydroxymethylpterin as reported by the above-mentioned authors. Furthermore, the urinary component which correlates to the status of malignant disease has to be interpreted as being neopterin. This conclusion can be drawn from previous studies conducted by the authors' laboratory.
饶及其同事报告了一种用于检测恶性肿瘤的诊断测试。特雷汉及其同事对该测试进行了扩展，将其作为接受抗白血病药物治疗的急性髓性白血病患者疾病状态的一个指标。作者能够证明，通过使用所述测定法，可以测量各种蝶啶，而并非如上述作者所报告的那样仅测量6 - 羟甲基蝶呤。此外，与恶性疾病状态相关的尿液成分必须被解释为新蝶呤。这一结论可从作者实验室先前进行的研究中得出。
